Register to join MSU and Dr. Victoria Werth live, online for "Skin findings seen with myositis autoantibodies and treatment...
Join us live on our YouTube LIVE channel Sunday, May 26, 2019, starting at 2 PM EDT for “A...
Myositis Patient Video Support Session, May 18th at 2 PM ET. The session is tailored to those diagnosed with...
Myositis Patient Video Support Session, May 7th at 7PM ET. Session is tailored to those diagnosed with or suspected...
Myositis Patient Video Support Session, April 10th. Session is tailored to those diagnosed with or suspected of having Polymyositis,...
Myositis Patient Video Support Session, March 16th. Session is tailored to those diagnosed with or suspected of having Polymyositis,...
Myositis Patient Video Support Session, March 6th. Session is tailored to those diagnosed with or suspected of having Polymyositis,...
Myositis Patient Video Support Session, Feb. 16th. Session is tailored to those diagnosed with or suspected of having Polymyositis,...
Myositis Patient Video Support Session, Feb. 6th. Session is tailored to those diagnosed with or suspected of having Polymyositis,...
DETERMINE - a Phase 3 trial designed to evaluate the efficacy and safety of lenabasum for the treatment of adults...
Myositis Patient Video Support Session, Jan. 19th. Session is tailored to those diagnosed with or suspected of having Polymyositis,...
Myositis Patient Video Support Session, Jan. 9th. Session is tailored to those diagnosed with or suspected of having Polymyositis,...
Patients diagnosed with Polymyositis, Dermatomyositis, Necrotizing Autoimmune Myopathy, Juvenile Myositis, and other unspecified or nonspecific idiopathic inflammatory myopathies (myositis),...
Corbus launches DETERMINE, a Phase 3 trial of lenabasum for the treatment of dermatomyositis
, , Dermatomyositis, Featured, News
New locations announced. DETERMINE is a double-blind, placebo-controlled 1-year study designed to test the efficacy and safety of lenabasum...
Myositis and Cancer: Risk highest for carriers of anti-TIF1 antibody
, , Dermatomyositis, Featured, News
The research found that DM patients with the anti-transcriptional intermediary factor 1 (anti-TIF1) antibody were more than three times...
Patients diagnosed with Polymyositis, Dermatomyositis, Necrotizing Autoimmune Myopathy, Juvenile Myositis, and other unspecified or nonspecific idiopathic inflammatory myopathies (myositis),...
During Myositis Awareness Month, May 2018, we placed a large focus on patient education by hosting some of the...
Myositis Patients, Join us for our Myositis Patient Live Video Support Session on November 17, 2018, starting at 2PM...
Patients diagnosed with Polymyositis, Dermatomyositis, Necrotizing Autoimmune Myopathy, Juvenile Myositis, and other unspecified or nonspecific idiopathic inflammatory myopathies (myositis),...
EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
, , Featured, News
Clinical trials and studies require patient groups in clearly defined categories, but the multiple diagnostic and classification criteria used...
Get Support!
Upcoming Events
-
A Day of Remembrance
May 26 @ 2:00 pm - 3:00 pm EDT -
Skin findings seen with myositis autoantibodies and treatment of skin in dermatomyositis
May 28 @ 4:00 pm - 5:00 pm EDT
